ABCR  Vol.5 No.4 , October 2016
How Does the Cortactin Gene Expression Affect Breast Cancer among Iranian Females?
Abstract: Introduction: Breast cancer is the most common cancer in the Iranian female population, and the incidence of the disease is rising. Early detection in association with staging or grading the tumor is the most effective method to increase survival rates. Studies have revealed that cortactin overexpression may play a role in the final stages of tumor progression and affects invasion and cellular motility. The aim of this study is to evaluate cortactin gene expression among Iranian female patients with breast cancer. Materials and Methods: Samples belonging to 70 breast cancer patients were randomly selected from the Imam Khomeini tumor bank. Normal and tumor tissues were prepared and stored at -80°C. Cortactin gene expression was evaluated by real-time PCR. Finally the data, along with demographic and clinical parameters, were analyzed using Prism 5.0 software, followed by t-test and ANOVA analysis. Results: Cortactin gene expression among tumor tissues increased 95.71% in comparison with normal tissues. A significant correlation between cortactin gene expression and lymph nodes’ involvement (P = 0.0077) and tumor stage (P = 0.0030) was observed. However, tumor grade (P = 0.8598), tumor size (P = 0.3058), and patient’s age (P = 0.4135) had no significant correlation with the gene’s expression level. Discussion: This study demonstrated that the cortactin gene’s overexpression in breast cancer may enhance lymph nodes’ involvement. This study also found that the gene’s expression was raised significantly in progressed stages of the cancer. Therefore, cortactin gene overexpression is an important factor indicating breast cells’ invasion. Conclusion: The cortactin gene’s expression level can be considered an accurate indicator for female breast cancer and also an appropriate biomarker for this cancer in clinical evaluations.
Cite this paper: Sara, T. , Mojtaba, S. , Mahta, M. , Parisa, N. , Bahareh, N. , Reza, S. and Nasrin, G. (2016) How Does the Cortactin Gene Expression Affect Breast Cancer among Iranian Females?. Advances in Breast Cancer Research, 5, 142-149. doi: 10.4236/abcr.2016.54017.

[1]   Mendis, S., Davis, S. and Norrving, B. (2015) Organizational Update The World Health Organization Global Status Report on Noncommunicable Diseases 2014; One More Landmark Step in the Combat Against Stroke and Vascular Disease. Stroke, 46, e121-e122.

[2]   Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. and Jemal, A. (2015) Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108.

[3]   Riley, L., Guthold, R., Cowan, M., Savin, S., Bhatti, L., Armstrong, T., et al. (2016) The World Health Organization STEPwise Approach to Noncommunicable Disease Risk-Factor Surveillance: Methods, Challenges, and Opportunities. American Journal of Public Health, 106, 74-78.

[4]   Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30.

[5]   Lam, W., Chan, C., Chan, C., Mak, C., Chong, K., Leung, M., et al. (2008) Factors Affecting the Palpability of Breast Lesion by Self-Examination. Singapore Medical Journal, 49, 228.

[6]   Anderson, B.O. and Jakesz, R. (2008) Breast Cancer Issues in Developing Countries: An Overview of the Breast Health Global Initiative. World Journal of Surgery, 32, 2578-2585.

[7]   Rizwan, M. and Saadullah, M. (2009) Lack of Awareness about Breast Cancer and Its Screening in Developing Countries. Indian Journal of Cancer, 46, 252.

[8]   Montazeri, A., Vahdaninia, M., Harirchi, I., Harirchi, A.M., Sajadian, A., Khaleghi, F., et al. (2008) Breast Cancer in Iran: Need for Greater Women Awareness of Warning Signs and Effective Screening Methods. Asia Pacific Family Medicine, 7, 1.

[9]   Harirchi, I., Ebrahimi, M., Zamani, N., Jarvandi, S. and Montazeri, A. (2000) Breast Cancer in Iran: A Review of 903 Case Records. Public Health, 114, 143-145.

[10]   Mousavi, S.M., Montazeri, A., Mohagheghi, M.A., Jarrahi, A.M., Harirchi, I., Najafi, M., et al. (2007) Breast Cancer in Iran: An Epidemiological Review. The Breast Journal, 13, 383-391.

[11]   Gotzsche, P.C. and Jorgensen, K.J. (2013) Screening for Breast Cancer with Mammography. John Wiley & Sons, Hoboken.

[12]   Li, C., Uribe, D. and Daling, J. (2005) Clinical Characteristics of Different Histologic Types of Breast Cancer. British Journal of Cancer, 93, 1046-1052.

[13]   Singletary, S.E. and Connolly, J.L. (2006) Breast Cancer Staging: Working with the Sixth Edition of the AJCC Cancer Staging Manual. CA: A Cancer Journal for Clinicians, 56, 37-47.

[14]   Tanase, K., Thies, E.D., Mader, U., Reiners, C. and Verburg, F.A. (2016) The TNM System (Version 7) Is the Most Accurate Staging System for the Prediction of Loss of Life Expectancy in Differentiated Thyroid Cancer. Clinical Endocrinology, 84, 284-291.

[15]   Wang, M., Klevebring, D., Lindberg, J., Czene, K., Gronberg, H. and Rantalainen, M. (2016) Determining Breast Cancer Histological Grade from RNA-Sequencing Data. Breast Cancer Research, 18, 1.

[16]   Islam, M.S., Kabir, E., Jeba, R., Islam, M.N., Khan, H.R. and Begum, S. (2015) Grading of Breast Cancer—A Short Review. Sir Salimullah Medical College Journal, 15, 95-99.

[17]   Calonge, N., Petitti, D.B., DeWitt, T.G., Dietrich, A.J., Gregory, K.D., Grossman, D., et al. (2009) Screening for Breast Cancer. Annals of Internal Medicine, 151, 716-726.

[18]   Li, Y., Tondravi, M., Liu, J., Smith, E., Haudenschild, C.C., Kaczmarek, M., et al. (2001) Cortactin Potentiates Bone Metastasis of Breast Cancer Cells. Cancer Research, 61, 6906-6911.

[19]   Dedes, K.J., Lopez-Garcia, M.-A., Geyer, F.C., Lambros, M.B., Savage, K., Vatcheva, R., et al. (2010) Cortactin Gene Amplification and Expression in Breast Cancer: A Chromogenic in Situ Hybridisation and Immunohistochemical Study. Breast Cancer Research and Treatment, 124, 653-666.

[20]   Sheen-Chen, S.-M., Huang, C.-Y., Liu, Y.-Y., Huang, C.-C. and Tang, R.-P. (2011) Cortactin in Breast Cancer: Analysis with Tissue Microarray. Anticancer Research, 31, 293-297.

[21]   MacGrath, S.M. and Koleske, A.J. (2012) Cortactin in Cell Migration and Cancer at a Glance. Journal of Cell Science, 125, 1621-1626.

[22]   Daly, R. (2004) Cortactin Signalling and Dynamic Actin Networks. Biochemical Journal, 382, 13-25.

[23]   Zhao, G., Huang, Z.-M., Kong, Y.-L., Wen, D.-Q., Li, Y., Ren, L., et al. (2013) Cortactin Is a Sensitive Biomarker Relative to the Poor Prognosis of Human Hepatocellular Carcinoma. World Journal of Surgical Oncology, 11, 74.

[24]   Ormandy, C.J., Musgrove, E.A., Hui, R., Daly, R.J. and Sutherland, R.L. (2003) Cyclin D1, EMS1 and 11q13 Amplification in Breast Cancer. Breast Cancer Research and Treatment, 78, 323-335.

[25]   Hirakawa, H., Shibata, K. and Nakayama, T. (2009) Localization of Cortactin Is Associated with Colorectal Cancer Development. International Journal of Oncology, 35, 1271-1276.

[26]   Tsai, W.-C., Jin, J.-S., Chang, W.-K., Chan, D.-C., Yeh, M.-K., Cherng, S.-C., et al. (2007) Association of Cortactin and Fascin-1 Expression in Gastric Adenocarcinoma: Correlation with Clinicopathological Parameters. Journal of Histochemistry & Cytochemistry, 55, 955-962.

[27]   Noh, S.J., Baek, H.A., Park, H.S., Jang, K.Y., Moon, W.S., Kang, M.J., et al. (2013) Expression of SIRT1 and Cortactin Is Associated with Progression of Non-Small Cell Lung Cancer. Pathology-Research and Practice, 209, 365-370.